A recent study has revealed that despite longstanding safety warnings, a significant number of dementia patients in the U.S. are still being prescribed potentially harmful drugs. The study, published in the American Medical Association Journal, highlights that about 25% of dementia patients were given medications known to increase the risk of delirium, falls, and hospitalizations between 2013 and 2021. These findings underscore the urgent need to improve prescription practices for vulnerable populations.
Ongoing Use of High-Risk Drugs in Dementia Treatment
For years, medical guidelines have cautioned against the use of certain central nervous system stimulants in older patients, particularly those with dementia, due to their increased risks. These drugs include antipsychotics, benzodiazepines, and certain antidepressants, such as doxepin and imipramine. However, the new study estimates that roughly 25% of dementia patients enrolled in Medicare were still prescribed at least one of these “potentially inappropriate” medications.
While the overall prescription rates for these medications have decreased slightly from 20% to 16% over the study period, the figures remain high, particularly for those with cognitive impairment. The research suggests that even though the number of prescriptions has fallen, patients continue to face risks due to these drugs.
Lack of Clinical Justification for High Prescription Rates
The study found that over two-thirds of the patients prescribed these drugs in 2021 lacked a documented clinical reason for their prescriptions, raising concerns about the appropriateness of these medications. Dr. John M. Mafi, the lead author of the study, emphasized that many patients with cognitive impairments are particularly vulnerable to these medications’ adverse effects, yet prescriptions for them remain prevalent.
Possible Explanations and Limitations of the Study
The study authors acknowledge a few limitations, such as the exclusion of Medicare Advantage plan recipients and the possibility that some prescriptions may have been issued for reasons not fully captured in the data. While doctors may have understood the risks involved, they may have resorted to these medications as a necessary evil when no better alternatives were available. Additionally, some dementia symptoms that would require medication may not be fully reflected in the Medicare claims data.
Conclusion
The continued prescription of risky medications to dementia patients reflects gaps in healthcare quality and the need for improved prescription practices. While the decrease in prescription rates over time is encouraging, it remains clear that significant improvements are necessary to ensure the safety of older patients, particularly those with cognitive impairments. This study serves as a reminder that more needs to be done to address the risks and enhance care for vulnerable populations.
